RU2502799C2 - Способ перепрограммирования соматических клеток - Google Patents

Способ перепрограммирования соматических клеток Download PDF

Info

Publication number
RU2502799C2
RU2502799C2 RU2009140903/10A RU2009140903A RU2502799C2 RU 2502799 C2 RU2502799 C2 RU 2502799C2 RU 2009140903/10 A RU2009140903/10 A RU 2009140903/10A RU 2009140903 A RU2009140903 A RU 2009140903A RU 2502799 C2 RU2502799 C2 RU 2502799C2
Authority
RU
Russia
Prior art keywords
cell
cells
oct
exogenously
proteins
Prior art date
Application number
RU2009140903/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009140903A (ru
Inventor
Рудольф ДЖЭНИШ
Джейкоб ХАННА
Мариус ВЕРНИГ
Кристофер Дж. ЛЕНГНЕР
Александр МАЙССНЕР
Оливер Тобиас БРЭМБРИНК
Рут ФОРМАН
Original Assignee
Уайтхед Инститьют Фор Биомедикал Рисёч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайтхед Инститьют Фор Биомедикал Рисёч filed Critical Уайтхед Инститьют Фор Биомедикал Рисёч
Publication of RU2009140903A publication Critical patent/RU2009140903A/ru
Application granted granted Critical
Publication of RU2502799C2 publication Critical patent/RU2502799C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
RU2009140903/10A 2007-04-07 2008-04-07 Способ перепрограммирования соматических клеток RU2502799C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92212107P 2007-04-07 2007-04-07
US60/922,121 2007-04-07
US95934107P 2007-07-12 2007-07-12
US60/959,341 2007-07-12
US3606508P 2008-03-12 2008-03-12
US61/036,065 2008-03-12
PCT/US2008/004516 WO2008124133A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Publications (2)

Publication Number Publication Date
RU2009140903A RU2009140903A (ru) 2011-05-20
RU2502799C2 true RU2502799C2 (ru) 2013-12-27

Family

ID=39831277

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009140903/10A RU2502799C2 (ru) 2007-04-07 2008-04-07 Способ перепрограммирования соматических клеток

Country Status (9)

Country Link
US (5) US9382515B2 (OSRAM)
EP (3) EP3878949B1 (OSRAM)
JP (8) JP2010523117A (OSRAM)
CN (2) CN105861443A (OSRAM)
AU (1) AU2008236629B2 (OSRAM)
CA (2) CA3071055A1 (OSRAM)
MX (2) MX348010B (OSRAM)
RU (1) RU2502799C2 (OSRAM)
WO (1) WO2008124133A1 (OSRAM)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US20070044164A1 (en) 2005-05-31 2007-02-22 Cold Spring Harbor Laboratory Methods for producing microRNAs
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
EP3878949B1 (en) 2007-04-07 2025-06-04 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP3078738B1 (en) 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009067757A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
AU2008329562A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Sox2 protein
JP5626619B2 (ja) * 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
AU2008286249B2 (en) * 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
EP2276838A4 (en) * 2008-04-07 2012-02-01 Nupotential Inc RE-PROGRAMMING A CELL BY INDUCING A PLURIPOTENTIC GENE THROUGH RNA INTERFERENCE
US20100279404A1 (en) 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
EP3231869A1 (en) 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
EP2295538B1 (en) * 2008-07-07 2015-10-21 Takara Bio Inc. Method for production of pluripotent stem cell
US20110231944A1 (en) * 2008-09-04 2011-09-22 Riken B cell-derived ips cells and application thereof
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
WO2010056808A2 (en) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
WO2010075330A1 (en) 2008-12-23 2010-07-01 Segetis, Inc. Ketal amide compounds, methods of making, and applications
CA2753845C (en) * 2009-02-27 2019-10-29 Kyoto University Nuclear reprogramming substance comprising glis1
EP2408904B1 (en) * 2009-03-20 2017-10-18 Mesoblast, Inc. Production of reprogrammed pluripotent cells
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
WO2010124290A2 (en) * 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions and methods for deriving or culturing pluripotent cells
CA2767623C (en) 2009-07-09 2018-11-27 Whitehead Institute For Biomedical Research Compositions and methods for mammalian genetics and uses thereof
JP5709015B2 (ja) 2009-08-19 2015-04-30 国立大学法人大阪大学 角膜移植用シート
JP2013503198A (ja) 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
CA2779039A1 (en) 2009-10-29 2011-05-05 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
WO2011079307A2 (en) * 2009-12-23 2011-06-30 The Salk Institute For Biological Studies Methods and compositions for treating neurological disorders
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP2601289B1 (en) 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
CN103459611B (zh) 2010-09-17 2016-11-02 哈佛大学校长及研究员协会 对多能干细胞的效用和安全性进行表征的功能基因组学研究
WO2012060473A1 (en) 2010-11-04 2012-05-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2647699B1 (en) 2010-12-03 2020-04-01 Kyoto University Efficient method for establishing induced pluripotent stem cells
JP6273842B2 (ja) * 2011-02-25 2018-02-07 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法
CN102731653B (zh) * 2011-04-06 2013-12-11 李凌松 一种抗磷酸化Oct4蛋白的抗体及其应用
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
BR112014013664A2 (pt) 2011-12-05 2020-11-03 Factor Bioscience Inc. métodos e produtos para transfectar células
WO2013109763A2 (en) * 2012-01-17 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Activation of innate immunity for nuclear reprogramming of somatic cells
KR20150045935A (ko) * 2012-04-24 2015-04-29 더 브리검 앤드 우먼즈 하스피털, 인크. 다능성 세포를 다시 생성하는 방법
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
JPWO2014057997A1 (ja) 2012-10-09 2016-09-05 仲信 林 初期化ペプチド及びその用途
WO2014066848A1 (en) 2012-10-25 2014-05-01 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
BR122019025681B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
US9857360B2 (en) 2013-01-25 2018-01-02 Xcell Biosciences, Inc. Cancer analysis system
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2903025C (en) * 2013-03-11 2025-10-07 Regeneron Pharmaceuticals, Inc. TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES
US11047848B2 (en) 2013-03-15 2021-06-29 Whitehead Institute For Biomedical Research Cellular discovery platform for neurodegenerative diseases
CN105531365A (zh) 2013-04-23 2016-04-27 耶达研究及发展有限公司 分离的幼稚多能干细胞和产生所述细胞的方法
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
WO2014200905A2 (en) 2013-06-10 2014-12-18 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
JP6611170B2 (ja) 2013-09-12 2019-11-27 株式会社カネカ 人工多能性幹細胞の分化誘導方法及び選別方法
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
WO2015120225A1 (en) 2014-02-10 2015-08-13 The Board Of Trustees Of The Leland Stanford Junior University ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA
IL247890B2 (en) 2014-03-19 2024-08-01 Vcell Therapeutics Inc Methods related to stem cells
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
WO2016040794A1 (en) 2014-09-12 2016-03-17 Whitehead Institute For Biomedical Research Cells expressing apolipoprotein e and uses thereof
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
CN112481211B (zh) 2015-01-26 2024-07-05 儿童医院公司 免疫调节性提高的细胞及其使用和生产方法
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
CA3019311A1 (en) * 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
US20170044609A1 (en) * 2015-04-24 2017-02-16 California Institute Of Technology Reactivation of x chromosome genes
EP3286310A4 (en) 2015-04-24 2019-01-09 California Institute of Technology REACTIVATION OF X-CHROMOSOME GENES
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
WO2017044853A1 (en) * 2015-09-09 2017-03-16 Trustees Of Tufts College Methods of generating neural stem cells
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105624117A (zh) * 2016-01-18 2016-06-01 哈尔滨医科大学 一种低氧促进小鼠成纤维细胞重编程为心肌细胞的方法
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US20170369904A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
AU2017313912B2 (en) 2016-08-19 2024-01-04 Whitehead Institute For Biomedical Research Methods of editing DNA methylation
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN106544315A (zh) * 2016-10-12 2017-03-29 广东艾时代生物科技有限责任公司 一种脂肪间充质干细胞诱导成多能干细胞的方法
JP2019537427A (ja) 2016-10-27 2019-12-26 カリフォルニア インスティチュート オブ テクノロジー Ｘ染色体の再活性化のためのｈｄａｃ阻害剤組成物
CN118203699A (zh) 2016-12-16 2024-06-18 伊维瓦医疗有限公司 用于基底膜支架的薄膜插入
EP3565891B1 (en) 2017-01-09 2023-04-12 Whitehead Institute for Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
US20190390169A1 (en) 2017-03-03 2019-12-26 Kyoto University Pancreatic progenitor cell production method
DK3607055T3 (da) * 2017-04-05 2025-08-18 Asgard Therapeutics Ab Sammensætninger til omprogrammering af celler til dendritiske celler eller antigenpræsenterende celler, fremgangsmåder og anvendelser deraf
WO2018195210A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
EP3640318A4 (en) 2017-06-14 2021-03-17 Takeda Pharmaceutical Company Limited CELL SEALING DEVICE
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
PL241125B1 (pl) 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
EP3719120A4 (en) 2017-11-30 2021-08-11 Kyoto University METHOD OF CULTIVATION OF CELLS
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
WO2019124540A1 (ja) 2017-12-22 2019-06-27 国立大学法人京都大学 細胞培養装置、培養液アスピレータ及び細胞培養方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
TW201945536A (zh) 2018-03-19 2019-12-01 國立大學法人京都大學 水凝膠膠囊
JP7257698B2 (ja) 2018-03-30 2023-04-14 オリヅルセラピューティクス株式会社 複素環化合物
WO2019189554A1 (ja) 2018-03-30 2019-10-03 国立大学法人京都大学 心筋細胞成熟促進剤
CN111971392A (zh) 2018-03-30 2020-11-20 国立大学法人京都大学 细胞的制造方法
BR112020021802A2 (pt) 2018-04-23 2021-02-23 Kyoto University métodos para produzir uma população de células produtoras de insulina ou uma população de células beta pancreáticas e para diminuir o número ou inibir a proliferação de células positivas para ki67, e, população de células progenitoras pancreáticas ou células em um estágio posterior de diferenciação
CA3108679A1 (en) 2018-08-03 2020-02-06 Kyoto University Cell production method
JP7436990B2 (ja) 2018-08-10 2024-02-22 国立大学法人京都大学 カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
TW202016293A (zh) 2018-08-10 2020-05-01 國立大學法人京都大學 Ｃｄ３陽性細胞的製造方法
EA202190582A1 (ru) 2018-08-22 2021-05-27 Киото Юниверсити Способ получения энтеральных нейральных клеток-предшественников
KR20210053925A (ko) 2018-08-31 2021-05-12 노일 이뮨 바이오테크 가부시키가이샤 Car 발현 t 세포 및 car 발현 벡터
AU2019343003B2 (en) 2018-09-19 2025-07-17 Orizuru Therapeutics, Inc. Insulin-producing cells
AU2019342197B2 (en) 2018-09-21 2025-10-16 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins
JP7553918B2 (ja) 2018-10-15 2024-09-19 公立大学法人横浜市立大学 栄養組成物
US20220089672A1 (en) 2018-12-27 2022-03-24 Kyoto University T-cell receptor modified object
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
WO2020158914A1 (ja) 2019-02-01 2020-08-06 国立大学法人京都大学 細胞の検出方法
CN113748213A (zh) 2019-03-29 2021-12-03 公立大学法人横滨市立大学 筛选方法及毒性评价方法
WO2020209389A1 (ja) 2019-04-10 2020-10-15 国立大学法人京都大学 生体組織様構造体の製造方法
JP2022535192A (ja) 2019-05-14 2022-08-05 アレフ ファームス リミテッド 多能性細胞凝集体およびそれらの使用
US20220313733A1 (en) 2019-06-11 2022-10-06 Kyoto University Method for producing renal interstitial cell
KR20220039719A (ko) 2019-07-03 2022-03-29 팩터 바이오사이언스 인크. 양이온성 지질 및 이의 용도
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US12421497B2 (en) 2019-08-20 2025-09-23 Orizuru Therapeutics, Inc. Method for enriching cardiac myocytes
WO2021079874A1 (ja) 2019-10-21 2021-04-29 武田薬品工業株式会社 増殖抑制剤
JP7723935B2 (ja) 2019-11-01 2025-08-15 国立大学法人京都大学 Ｔ細胞の製造方法
CN114761560A (zh) 2019-11-25 2022-07-15 国立大学法人京都大学 T细胞主细胞库
US20230136878A1 (en) 2020-03-19 2023-05-04 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
US20230212519A1 (en) 2020-03-19 2023-07-06 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
WO2021200901A1 (ja) 2020-03-31 2021-10-07 国立大学法人京都大学 Ｔ前駆細胞の製造方法
CN115803426A (zh) 2020-05-28 2023-03-14 千纸鹤治疗公司 均一尺寸的细胞聚集体的大量制造方法
CN112201307B (zh) * 2020-09-23 2024-09-17 温州医科大学 一种转录本注释方法以及筛选长非编码rna和内源逆转录病毒来源长非编码rna的方法
US20230399607A1 (en) 2020-11-20 2023-12-14 Orizuru Therapeutics, Inc. Maturation agent
US20240318141A1 (en) 2021-02-09 2024-09-26 Orizuru Therapeutics, Inc. Maturation agent
CN116964193A (zh) 2021-03-09 2023-10-27 国立大学法人东京医科齿科大学 细胞簇的制造方法
JPWO2022215718A1 (OSRAM) 2021-04-08 2022-10-13
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
WO2022230919A1 (ja) 2021-04-28 2022-11-03 国立大学法人 東京医科歯科大学 細胞の製造方法
CN113278686A (zh) * 2021-06-11 2021-08-20 扬州大学 一种研究dna甲基化调控重编程过程的方法
TW202330910A (zh) 2021-09-27 2023-08-01 國立大學法人京都大學 Ｔ細胞的製造方法
WO2023149555A1 (ja) 2022-02-04 2023-08-10 国立大学法人京都大学 Ｔ細胞の製造方法
EP4497822A1 (en) 2022-03-23 2025-01-29 Kyoto University Method for producing regulatory t cells
US20250188420A1 (en) 2022-04-25 2025-06-12 Orizuru Therapeutics, Inc. Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
US20250332259A1 (en) 2022-06-17 2025-10-30 Kyoto University Thymic epithelial cell production method
IL318270A (en) 2022-07-14 2025-03-01 Orizuru Therapeutics Inc Fibrin gel sheet for cell transplantation
EP4563697A4 (en) 2022-07-25 2025-11-12 Univ Kyoto IN VITRO CULTURE METHOD FOR INDUCING OVARIAN FOLLICLES FROM PRIMATE FETAL OVARIAN CELLS
EP4563703A4 (en) 2022-07-26 2025-09-24 Univ Kyoto ARTIFICIAL RECEIVER HAVING A LOAD-SHEDDING STRUCTURE
CN120051562A (zh) 2022-08-05 2025-05-27 国立大学法人京都大学 用于产生心肌的方法
WO2024034559A1 (ja) 2022-08-08 2024-02-15 株式会社ヘリオス 細胞凝集塊の製造方法
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
WO2024070494A1 (ja) 2022-09-26 2024-04-04 国立大学法人京都大学 膵内胚葉細胞の製造方法
EP4600352A1 (en) 2022-09-26 2025-08-13 Kyoto University T cell production method
JPWO2024071280A1 (OSRAM) 2022-09-29 2024-04-04
WO2024106444A1 (ja) 2022-11-16 2024-05-23 学校法人関西医科大学 着床促進薬とそのスクリーニング系
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025106897A1 (en) * 2023-11-16 2025-05-22 Colossal Biosciences Inc. Methods and compositions for creating induced pluripotent stem cells
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2249039C2 (ru) * 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
US20070032447A1 (en) * 2005-08-01 2007-02-08 Eilertsen Kenneth J Production of reprogrammed cells with restored potential

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
WO1995003402A1 (en) * 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9517779D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9809178D0 (en) 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
JP2002529070A (ja) * 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ 胚性幹細胞
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US20020168660A1 (en) 2001-02-15 2002-11-14 Whitehead Institute For Biomedical Research Stem cell self-renewal and lineage commitment
US20020137460A1 (en) * 2001-03-08 2002-09-26 Howard Sun Universal multi-band (5 bands and more) keyless RF remote control unit using bluetooth radio module as the base
US7250255B2 (en) 2001-05-31 2007-07-31 Shinya Yamanaka Genes with ES cell-specific expression
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
AU2002330465B2 (en) 2001-09-21 2006-07-27 Kyoto University Screening method for a reprogramming agent, reprogramming agent screened by the method, method for using the reprogramming agent, method for differentiating an undifferentiated fusion cell, and production method of cells, tissues and organs.
DE10162080A1 (de) * 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
GB0202149D0 (en) * 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0211904D0 (en) * 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
AU2003247135A1 (en) 2002-07-23 2004-02-09 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
AU2004252568B2 (en) * 2003-06-27 2011-06-30 Ethicon, Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
WO2005080598A1 (ja) 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
AU2005224569B2 (en) * 2004-03-23 2011-07-14 Toshihiro Akaike Method of proliferating pluripotent stem cell
US20060148104A1 (en) 2004-10-29 2006-07-06 Massachusetts Institute Of Technology Detection of ion channel or receptor activity
AU2006243810B2 (en) * 2005-04-29 2012-06-07 Monash University A method for producing stem cells or stem cell-like cells from mammalian embryos
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
EP4223769A3 (en) * 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US7875741B2 (en) 2006-06-27 2011-01-25 Jawaharlal Nehru Centre For Advanced Scientific Research Site-specific inhibitors of histone methyltransferase [HMTase] and process of preparation thereof
CN101743306A (zh) * 2007-03-23 2010-06-16 威斯康星校友研究基金会 体细胞重编程
EP3878949B1 (en) 2007-04-07 2025-06-04 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
US20120282229A1 (en) * 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP3078738B1 (en) * 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
US9534205B2 (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
US20100279404A1 (en) 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
EP3231869A1 (en) * 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
US20120034192A1 (en) * 2008-09-19 2012-02-09 Young Richard A Compositions and methods for enhancing cell reprogramming
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2249039C2 (ru) * 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
US20070032447A1 (en) * 2005-08-01 2007-02-08 Eilertsen Kenneth J Production of reprogrammed cells with restored potential

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SAVARESE ЕТ AL.: 'Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X inactivation' MOLECULAR AND CELLULAR BIOLOGY vol. 26, no. 19, October 2006, pages 7167-7177. *
TAKAHASHI K. ЕТ AL.: 'Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors' CELL vol. 126, no. 4, 25 August 2006, pages 663-676. *
TAKAHASHI K. ЕТ AL.: 'Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors' CELL vol. 126, no. 4, 25 August 2006, pages 663-676. SAVARESE ЕТ AL.: 'Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X inactivation' MOLECULAR AND CELLULAR BIOLOGY vol. 26, no. 19, October 2006, pages 7167-7177. *

Also Published As

Publication number Publication date
US20190241874A1 (en) 2019-08-08
CN101932705A (zh) 2010-12-29
CA2683056A1 (en) 2008-10-16
EP3878949A1 (en) 2021-09-15
JP2024024049A (ja) 2024-02-21
MX2009010847A (es) 2010-04-27
CN105861443A (zh) 2016-08-17
WO2008124133A1 (en) 2008-10-16
EP2626416A2 (en) 2013-08-14
JP2022031941A (ja) 2022-02-22
JP2017035113A (ja) 2017-02-16
JP2020014479A (ja) 2020-01-30
EP2145000A4 (en) 2010-05-05
EP2626416A3 (en) 2013-12-18
US20110076678A1 (en) 2011-03-31
JP6934501B2 (ja) 2021-09-15
EP3878949B1 (en) 2025-06-04
MX348010B (es) 2017-05-23
EP2145000A1 (en) 2010-01-20
MX352541B (es) 2017-11-29
US20170342386A1 (en) 2017-11-30
JP2015051022A (ja) 2015-03-19
CA3071055A1 (en) 2008-10-16
RU2009140903A (ru) 2011-05-20
US20150118755A1 (en) 2015-04-30
US9714414B2 (en) 2017-07-25
US10093904B2 (en) 2018-10-09
US9382515B2 (en) 2016-07-05
AU2008236629A1 (en) 2008-10-16
JP2018086017A (ja) 2018-06-07
US20250188423A1 (en) 2025-06-12
AU2008236629B2 (en) 2014-03-06
CA2683056C (en) 2020-03-24
JP2020014480A (ja) 2020-01-30
JP2010523117A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
RU2502799C2 (ru) Способ перепрограммирования соматических клеток
Patel et al. Advances in reprogramming somatic cells to induced pluripotent stem cells
JP2017035113A5 (OSRAM)
Mao et al. Reprogramming stem cells in regenerative medicine
Cheng et al. Protecting against wayward human induced pluripotent stem cells with a suicide gene
Kramer et al. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury
ES2900277T3 (es) Producción de células pluripotentes reprogramadas
Abou-Saleh et al. The march of pluripotent stem cells in cardiovascular regenerative medicine
Stocum et al. Stretching the limits: stem cells in regeneration science
US12404507B2 (en) Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
JP7579935B2 (ja) Ｃｒｉｓｐｒ活性化による人工多能性細胞の生成
WO2012079278A1 (zh) 诱导性多能干细胞的制备方法以及用于制备诱导性多能干细胞的培养基
Anastasia et al. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine
WO2019213505A1 (en) Enhancement of fibroblast plasticity for treatment of disc degeneration
US20090180996A1 (en) Epigenetic modification of cell phenotype, fate and/or function by RNA transfer
Wang et al. Reprogramming of mouse renal tubular epithelial cells to induced pluripotent stem cells
WO2013004135A1 (zh) 诱导性多能干细胞的制备方法和用于制备诱导性多能干细胞的培养基
Kuzma-Hunt et al. Opening the “black box” underlying barriers to the use of canine induced pluripotent stem cells: a narrative review
Petersen et al. Generation of diverse neural cell types through direct conversion
Ramesh et al. Somatic cell dedifferentiation/reprogramming for regenerative medicine
Batubara Induced pluripotent stem cells and genome editing technology as therapeutic strategies for Duchenne muscular dystrophy
Heng et al. Induced adult stem (iAS) cells and induced transit amplifying progenitor (iTAP) cells—a possible alternative to induced pluripotent stem (iPS) cells?
WO2023194618A1 (en) METHOD OF GENERATING iPSC LINES WITH TOTIPOTENT PROPERTIES
Kang et al. Adipose stromal cells are a more efficient source than adipose stem cells in retrovirus-mediated iPS induction
Chronowska Induced pluripotent stem (iPS) cells in domestic animals-recent achievements-a review.